Dose-volume effects for normal tissues in external radiotherapy: Pelvis

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 153-167

  Fiorino, Claudio ^a   Valdagni, Riccardo ^b   Rancati, Tiziana ^b   Sanguineti, Giuseppe ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bladder; Dose volume histograms; Dose volume models in radiotherapy; Gynecological; Intensity modulated radiotherapy; NTCP; Optimisation in radiotherapy; Prostate; Rectum; Toxicity in radiotherapy

Indexed keywords

BLADDER; BLOOD TOXICITY; CANCER RADIOTHERAPY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FEMUR HEAD; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC PARAMETERS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PELVIS CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; RELIABILITY; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

ERECTILE DYSFUNCTION; FECAL INCONTINENCE; FEMALE; FEMUR HEAD; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; PELVIC BONES; PELVIC NEOPLASMS; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECTUM; URINARY BLADDER;

EID: 70350474994     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.08.004     Document Type: Review

References (199)

1. Burman C., Kutcher G.J., Emami B., et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21 (1991) 123-135
2. Jackson A. Partial irradiation of the rectum. Semin Radiat Oncol 11 (2001) 215-223
3. O'Brien P.C. Radiation injury of the rectum. Radiother Oncol 60 (2001) 1-14
4. Van der Wielen G.J., Mulhall J.P., and Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to penile structures: a critical review. Radiother Oncol 84 (2007) 107-113
5. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know?. Crit Rev Oncol Hematol 57 (2006) 165-173
6. Jackson A., Skwarchuk M., Zelefsky M., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
7. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
8. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose conformal radiotherapy for localized prostate cancer. J Radiat Oncol Biol Phys 57 (2003) 953-962
9. Rancati T., Fiorino C., Gagliardi G., et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 73 (2004) 21-32
10. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1297-1308
11. Peeters S.T.H., Hoogeman M., Heemsbergen W.D., et al. Rectal bleeding, fecal incontinence and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 66 (2006) 11-19
12. Söhn M., Yan D., Liang J., et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys 26 (2007) 1066-1073
13. Tucker S.L., Dong L., Bosch W.R., et al. Fit of a generalized Lyman Normal tissue complication probability (NTCP) model to grade ≥ 2 late rectal toxicity data from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69 (2007) S8-S9
14. Rancati T., Fiorino C., Valvassori V., et al. Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modeling. Radiother Oncol 88 (2008) S332-S333
15. Fiorino C., Fellin G., Rancati T., et al. Clinical and dosimetric predictors of late rectal syndrome after 3DCRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 70 (2008) 1130-1137
16. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
17. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129
18. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
19. Cahlon O., Hunt M., and Zelefsky M.J. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semim Radiat Oncol 18 (2008) 48-57
20. Hartford A.C., Niemierko A., Adams J.A., et al. Conformal irradiation of the prostate: estimating long term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys 36 (1996) 721-730
21. Boersma L.J., van den Brink M., Allison M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
22. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
23. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1009-1019
24. Zapatero A., Garcia-Vicente F., Modolell I., et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys 59 (2004) 1343-1351
25. Fenwick J.D., Khoo V.S., Nahum A.E., et al. Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 473-480
26. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late rectal bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
27. Wachter S., Gerstner N., Goldner G., et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 59 (2001) 65-70
28. Koper P.C.M., Heemsbergen W.D., Hoogeman M.S., et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1072-1082
29. Greco C., Mazzetta C., Cattani F., et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 69 (2003) 215-222
30. Kupelian P.A., Reddy C.A., Klein E.A., et al. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51 (2001) 988-993
31. Van der Laan H.P., van der Bergh A., Schilstra C., et al. Grading-system-dependent volume effects of late radiation induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1138-1145
32. Fiorino C., Vavassori V., Sanguineti G., et al. Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability. Radiother Oncol 63 (2002) 249-255
33. Foppiano F., Fiorino C., Frezza G., et al. The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys 57 (2003) 573-579
34. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
35. Heemsbergen W.D., Hoogeman M.S., Hart G.A., et al. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1011-1018
36. Peeters S.T.H., Lebesque J.V., Heemsbergen W.D., et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 1151-1161
37. Munbodh R., Jackson A., Bauer J., et al. Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity-modulated radiation therapy for prostate cancer. Med Phys 35 (2008) 2137-2150
38. van Lin E.N.J.T., Kristinsson J., Philippens M.E.P., et al. Reduced late rectal mucosal changes after three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 67 (2007) 78-83
39. Goldner G., Tomicek B., Becker G., et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna rectoscopy score and correlated with EORTC/RTOG score for late rectal toxicity. Int J Radiat Oncol Biol Phys 67 (2007) 78-83
40. Pickett B., Vigneault E., Kurhanewicz J., et al. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 44 (1999) 921-929
41. De Meerleer, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 75 (2005) 325-333
42. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
43. Koom W., Sohn D., Kyung K., et al. Computed tomography-based high-dose-rate intracavitary brachytherapy for uterine cervical cancer: preliminary demonstration of correlation between dose-volume parameters and rectal mucosal changes observed by flexible sigmoidoscopy. Int J Radiat Oncol Biol Phys 68 (2007) 1446-1454
44. Crosland A., and Jones R. Rectal bleeding: prevalence and consultation behaviour. BMJ 311 (1995) 486-488
45. Talley N.J., and Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. Am J Gastroenterol 93 (1998) 2179-2183
46. Kang J.Y., Rink E., Sundaram K.K., and Hartley I. Factors associated with the frequency of stool examination: effect on incidence of reported rectal bleeding. Eur J Gastroenterol Hepatol 15 (2003) 531-533
47. Fonteyne V., De Neve W., Geert V., et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 84 (2007) 156-163
48. Smit W.G., Pa Helle, van Putten W.L., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 (1990) 23-29
49. Sanguineti G., Agostinelli S., Foppiano F., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 86 (2002) 1843-1847
50. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
51. Lawton C.A., Bae K., Pilepich M., et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 70 (2008) 437-441
52. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
53. Schultheiss T.E., Hanks G.E., Hunt M.A., et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 32 (1995) 643-649
54. Sanguineti G., Marcenaro M., Franzone P., et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 66 (2003) 151-157
55. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49 (1997) 38-45
56. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 2460-2468
57. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: a predictor of late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
58. Moore, et al. Rectal bleeding after radiation therapy for prostate cancer: endoscopic evaluation. Radiology 217 (2000) 215-218
59. Vordemark D., Schwab M., Ness-Duurdoumas R., et al. Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiother Oncol 69 (2003) 209-214
60. Al Abany M., Helgason A.R., Agren Cronqvist A.K., et al. Dose to the anal-sphincter region and risk of fecal leakage. Acta Oncol 43 (2004) 117-118
61. Fellin G, Fiorino C, Rancati T, et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multi-center observational study. Radiother Oncol 2009; in press.
62. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the MD Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2008) 77-84
63. Karlsdottir A., Muren L.P., Wentzel-Larsen T., et al. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 70 (2008) 1478-1486
64. Michalsky J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG9406 dose level IV. Int J Radiat Oncol Biol Phys 58 (2004) 735-742
65. Sohn M., Alber M., and Yan D. Principal component analysis-based pattern analysis of dose-volume histograms and influence on rectal toxicity. Int J Radiat Oncol Biol Phys 69 (2007) 230-239
66. Wang C.J., Leung S.W., Chen H.C., et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys 40 (1998) 85-91
67. Heemsbergen W.D., Peeters S.T., Koper P.C., et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66 (2006) 3-10
68. Nuyttens J.J., Milito S., Rust P.F., and Turrisi III A.T. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
69. Karlsdóttir A., Johannessen D.C., Muren L.P., et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71 (2004) 43-53
70. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1142-1152
71. Vavassori V., Fiorino C., Rancati T., et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 67 (2007) 1401-1410
72. Cheng J.C., Schultheiss T.E., Nguyen K.H., and Wong J.Y. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 71 (2008) 351-357
73. Valdagni R., Rancati T., Fiorino C., et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3DCRT. Int J Radiat Oncol Biol Phys 71 (2008) 1065-1073
74. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
75. Lindsay P.E., Moiseenko V.V., Van Dyk J., et al. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Phys Med Biol 48 (2003) 507-522
76. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
77. Valdagni R., Italia C., Montanaro P., et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 75 (2005) 74-82
78. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
79. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44 (2005) 265-276
80. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
81. Arcangeli S., Strigari L., Soete G., et al. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 73 (2009) 39-45
82. Strigari L., Arcangeli G., Arcangeli S., and Benassi M. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 1454-1460
83. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res 104 (1985) S13-S19
84. Kutcher G.J., Burman C., Brewster L., et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 21 (1991) 137-146
85. Fellin G., Fiorino C., Rancati T., et al. Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modeling. Int J Radiat Oncol Biol Phys 72 (2008) S332 [Abstract]
86. Mavroidis P., Al-Abany M., Helgason A.R., et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol 181 (2005) 293-306
87. Kallman P., Agren A., and Brahme A. Tumor and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 62 (1992) 249-262
88. Li S., Boyer A., Lu Y., and Chen G.T.Y. Analysis of the dose-surface histogram and dose-wall histogram for the rectum and bladder. Med Phys 24 (1997) 1107-1116
89. MacKay R.I., Hendry J.H., Moore C.J., et al. Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms. Br J Radiol 70 (1997) 517-526
90. Meijer G.J., van der Brink M., Hoogeman M.S., Meinders J., and Lebesque J.V. Dose-wall histograms and normalized dose-surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy. Int J Radiat Oncol Biol Phys 45 (1999) 1073-1080
91. Wachter S., Gerstner N., Dorner D., et al. The influence of a rectal ballon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 91-100
92. Yan D., Xu B., Lockman D., et al. The influence of interpatient and intrapatient rectum variation on external beam treatment of prostate cancer. Int J Radiat Oncol Biol Phys 51 (2001) 1111-1119
93. Lebesque J.V., Allison D., Bruce A.M., et al. Variation in volumes, dose-volume histograms and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 33 (1995) 1109-1119
94. Lu Y., Spelbring D., Song P.Y., et al. Dose-surface histograms as treatment planning tool for prostate conformal therapy. Med Phys 22 (1995) 279-284
95. Fiorino C., Gianolini S., and Nahum A.E. A cylindrical model of the rectum: comparing dose-volume, dose-surface and dose-wall histograms in the radiotherapy of prostate cancer. Phys Med Biol 48 (2003) 2603-2616
96. Garcia-Vicente F., Zapatero A., Floriano A., et al. Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3DCRT in prostate cancer. Med Phys 32 (2005) 2503-2509
97. De Crevoisier R., Tucker S.L., Dong L., et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 965-973
98. Heemsbergen W.D., Hoogeman M.S., Witte M.G., et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. Int J Radiat Oncol Biol Phys 67 (2007) 1418-1424
99. Stasi M., Munoz F., Fiorino C., et al. Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol 80 (2006) 363-370
100. Nijkamp J., Pos F.J., Nuver T.T., et al. Adaptive radiotherapy for prostate cancer using kilovoltage con-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys 70 (2008) 75-82
101. Fiorino C., Di Muzio N., Broggi S., Cozzarini C., Maggiulli E., Alongi F., et al. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 71 (2008) 611-617
102. Rancati T., Foppiano F., Pasquino M., et al. Impact of uncertainties on rectal NTCP modeling: fitting clinical data with the Lyman model. Radiother Oncol 73 (2005) S54-S55
103. Rasch C., Remeijer P., Koper P.C.M., et al. Comparison of prostate cancer treatment in two Institutions: a quality control study. Int J Radiat Oncol Biol Phys 45 (1999) 1055-1062
104. Svensson J.P., Stalpers L.J.A., Lange R.E.E.E., et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med 3 (2006) e422
105. Hümmerich J., Werle-Schneider G., Popanda O., et al. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance. A pilot study in prostate cancer patients receiving radiotherapy. Int J Radiat Biol 82 (2006) 593-604
106. Cesaretti J.A., Stock R.G., Atencio D.P., et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1410-1416
107. Peters C.A., Stock R.G., Cesaretti J.A., et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 752-759
108. Damaraju S., Murray D., Dufour J., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12 (2006) 2545-2554
109. Burri R.J., Stock R.G., Cesaretti J.A., et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170 (2008) 49-59
110. Valdagni R., Rancati T., Ghilotti M., et al. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 74 (2009) 1431-1440
111. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
112. Marks L.B., Carroll P.R., Dugan T.C., and Anscher M.S. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31 (1995) 1257-1280
113. Cheung M.R., Tucker S.L., Dong L., et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1059-1065
114. Harsolia A., Vargas C., Yan D., et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys 69 (2007) 1100-1109
115. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
116. Lips I.M., Denhad H., van Glis C.H., et al. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 3 (2008) 15
117. Al Mangaani A., Heemsbergen W.D., Peeters S.T.H., and Lebesque J.V. Role of Intensity-modulated Radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 685-691
118. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
119. Heemsbergen W., Witte M., Al-Mamgani A., et al. GU toxicity after RT for prostate cancer: dose maps and dose surface data to identify dose-effect relationships. Radiother Oncol 88 (2008) S83-S84
120. Liu M., Pickles T., Agranovich A., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 59-67
121. Letschert J.G., Lebesque J.V., and Aleman B.M. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol 32 (1994) 116-123
122. Minsky B.D., Conti J.A., Huang Y., and Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 13 (1995) 1409-1416
123. Baglan K.L., Frazier R.C., Yan D., et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 52 (2002) 176-183
124. Roeske J.C., Bonta D., Mell L.K., et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Int J Radiat Oncol Biol Phys 69 (2003) 201-207
125. Sanguineti G., Endres E.J., Sormani M.P., and Parker B.C. Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. Strahlenther Onkol 185 (2009) 390-396
126. Huang E.Y., Sung C.C., Ko S.F., et al. The different volume effects of small-bowel toxicity during pelvic irradiation between gynaecological patients with and without abdominal surgery: a prospective study with computed-tomography-based dosimetry. Int J Radiat Oncol Biol Phys 69 (2007) 732-739
127. Tho L.M., Glegg M., Paterson J., et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 66 (2006) 505-513
128. Robertson J.M., Lockman D., Yan D., and Wallace M. The dose-volume relationships of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 70 (2008) 413-418
129. Fiorino C., Alongi F., Perna L., et al. Dose-volume relationship for acute bowel toxicity for patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 75 (2009) 29-35
130. Leichman C.G., Fleming T.R., Muggia F.M., et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13 (1995) 1303-1311
131. van Duijvendijk P., Slors F., Taat C.W., et al. A prospective evaluation of anorectal function after total mesorectal excision in patients with a rectal carcinoma. Surgery 133 (2003) 56-65
132. Vargas C., Yan D., Kestin L.L., et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys 63 (2005) 141-149
133. Muren L.P., Smaaland R., and Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol 69 (2003) 291-304
134. Kvinnsland Y., and Muren L.P. The impact of organ motion on intestine doses and complication probabilities in radiotherapy of bladder cancer. Radiother Oncol 76 (2005) 43-47
135. Hysing L.B., Kvinnsland Y., Lord H., et al. Planning organ at risk volume margins for organ motion of the intestine. Radiother Oncol 80 (2006) 349-354
136. Sanguineti G., Little M., Endres E.J., et al. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. Radiother Oncol 88 (2008) 95-101
137. Fokdal L., Honore H., Hoyer M., et al. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol 74 (2005) 203-210
138. Letschert J.G. The prevention of radiation-induced small bowel complications. Eur J Cancer 31A (1995) 1361-1365
139. Hysing L.B., Skorpen T.N., Alber M., et al. Influence of organ motion of conformal vs intensity-modulated pelvic radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 71 (2008) 1496-1503
140. Fisch B.M., Pickett B., Weinberg V., et al. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 57 (2001) 955-959
141. Pickett B., Fisch B.M., Weinberg V., et al. Dose to the bulb of the penis is associated with the risk of impotence following radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 263
142. Merrick G.S., Butler W.M., Wallner K.E., et al. The importance of radiation doses to the penile bulb vs. Crura in the development of post brachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 54 (2002) 1055-1062
143. Mangar S.A., Sydes M.R., Tucker H.L., et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer. Radiother Oncol 80 (2006) 355-362
144. Wernicke A.G., Valicenti R., DiEva K., et al. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1357-1363
145. Roach M., Winter K., Michalski J.M., et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 60 (2004) 1351-1356
146. Incrocci L., Slob A.K., and Levenday P.C. Sexual (dys) function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 52 (2002) 681-693
147. Kitelet R.A., Lee W.R., deGuzman A.F., et al. Radiation dose to neurovascula bundles of penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 1 (2002) 90-94
148. Selek U., Cheng R., Lii M., et al. Erectile dysfunction and radiation dose to the penile base structures: a lack of correlation. Int J Radiat Oncol Biol Phys 59 (2004) 1039-1046
149. Algan O., Hanks G.E., and Shaer A.H. Localization of the prostatic apex for radiation treatment planning. Int J Radiat Oncol Biol Phys 33 (1995) 925-930
150. Sethi A., Mohideen N., Leybovich L., and Mulhall J. Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys 55 (2003) 970-978
151. McLaughlin P., Narayana V., Meirovitz A., et al. Vessel-sparing prostate radiotherapy dose limitation to critical erectile vascular structures (internal pudental artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys 61 (2005) 20-31
152. Perna L., Fiorino C., Cozzarini C., et al. Sparing the penile bulb in the radical irradiation of clinically localized prostate carcinoma: a comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and helical tomotherapy. Radiother Oncol 93 (2009) 57-63
153. Zelefsky M.J., and Eid J.F. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 40 (1998) 129-133
154. Mulhall J.P., and Yonover P.M. Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy for prostate cancer. Urology 58 (2001) 828
155. Potosky A.L., Legler J., Albertsen P.C., et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92 (2000) 1582-1592
156. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163 (2000) 460-463
157. Goldstein I., Feldman M.I., Deckers P.J., et al. Radiation-associated impotence. A clinical study of its mechanism. JAMA 251 (1984) 903-910
158. Robinson J.W., Moritz S., and Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 54 (2002) 1063-1068
159. Rosen R.C., Riley A., Wagner G., et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
160. Litwin M.S., Lubeck D.P., Henning J.M., et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 159 (1998) 1988-1992
161. O'Carroll R., and Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry 145 (1984) 146-151
162. Saad F., Grahl A.S., Aversa A., et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int 99 (2007) 988-992
163. Aversa A., Isidori A.M., De Martino M.U., et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 53 (2000) 517-522
164. Yoon F.H., Perera F., Fisher B., et al. Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. Int J Radiat Oncol Biol Phys 74 (2009) 1186-1190
165. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362-367
166. Gulley J.L., Aragon-Ching J.B., Steinberg S.M., et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 180 (2008) 1432-1437 discussion 1437
167. Pickles T., and Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter?. J Urol 167 (2002) 2448-2452
168. Wilke D.R., Parker C., Andonowski A., et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 97 (2006) 963-968
169. Teloken P.E., Ohebshalom M., Mohideen N., et al. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 178 (2007) 2521-2525
170. Incrocci L., Koper P.C., Hop W.C., et al. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 51 (2001) 1190-1195
171. Daniell H.W., Clark J.C., Pereira S.E., et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 91 (2001) 1889-1895
172. Zagars G.K., and Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 39 (1997) 85-89
173. Boehmer D., Badakhshi H., Kuschke W., Bohsung J., and Budach V. Testicular dose in prostate cancer radiotherapy: impact on impairment of fertility and hormonal function. Strahlenther Onkol 181 (2005) 179-184
174. Herrmann T. Radiation reactions in the gonads: importance in patient counselling. Strahlenther Onkol 173 (1997) 493-501
175. Yau I., Vuong T., Garant A., et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. Int J Radiat Oncol Biol Phys 74 (2009) 1481-1486
176. Izard M.A. Leydig cell function and radiation: a review of the literature. Radiother Oncol 34 (1995) 1-8
177. Piroth M.D., Hensley F., Wannenmacher M., and Zierhut D. Male gonadal dose in adjuvant 3-D-pelvic irradiation after anterior resection of rectal cancer. Influence to fertility. Strahlenther Onkol 179 (2003) 754-759
178. Wo J.Y., and Viswanathan A.N. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 73 (2009) 1304-1312
179. Wallace W.H., Thomson A.B., Saran F., and Kelsey T.W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 62 (2005) 738-744
180. Bedford J.L., Khoo V.S., Webb S., and Dearnaley D.P. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 46 (2000) 231-238
181. Herman M.P., Kopetz S., Bhosale P.R., et al. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys 74 (2009) 818-823
182. Baxter N.N., Habermann E.B., Tepper J.E., et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 294 (2005) 2587-2593
183. Small Jr. W., and Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research?. JAMA 294 (2005) 2635-2637
184. Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26 (2008) 5465-5476
185. Mell L.K., Kochanski J.D., Roeske J.C., et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 1356-1365
186. Sacks E.L., Goris M.L., Glatstein E., et al. Bone marrow regeneration following large field radiation: influence of volume, age, dose and time. Cancer 42 (1978) 1057-1065
187. Rubin P., Landman S., Mayer E., et al. Bone marrow regeneration and extension after extended field irradiation in Hodgking's disease. Cancer 32 (1973) 699-711
188. Brixey C.J., Roeske J.C., Lujan A.E., et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynaecologic cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1388-1396
189. Lujan A.E., Mundt A.J., Yamada S.D., et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 516-521
190. Ahmed R.S., Kim R.Y., Duan J., et al. IMRT dose escalation for positive paraortic lymphnodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 60 (2004) 505-512
191. Roeske J.C., Lujan A.E., Reba R.C., et al. Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynaecologic malignancies. Radiother Oncol 77 (2005) 11-17
192. Mell L.K., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1431-1437
193. Mutyala S., Thawani N., Vainsthein J.M., et al. Dose constraints recommendations and a predictive nomogram of incidence of hematological toxicity for cervix cancer patients treated with concurrent cisplatin and intensity modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 72 (2008) S359-S360
194. Shasha D., Homel P., Wagner J.R., et al. Predictors of anemia in patients treated with radiation for prostate cancer. Int J Radiat Oncol Biol Phys 51 (2001) S298-S299
195. Choo R., Chander S., Danjoux C., et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate patients?. Can J Urol 12 (2005) 2547-2552
196. Dunphy E.P., Petersen I.A., Cox R.S., and Bagshaw M.A. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 16 (1989) 1173-1178
197. Pai H.H., Ludgate C., Pickles T., Paltiel C., et al. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 990-998
198. Valdagni R., Rancati T., Fiorino C., et al. Development of nomograms to predict moderate/severe late rectal bleeding in prostate cancer patients undergoing 3DCRT. Radiother Oncol 88 (2008) S150
199. Valdagni R., Rancati T., and Fiorino C. Predictive models of toxicity in external radiotherapy for prostate cancer: clinical issues. Cancer 115 (2009) 3141-3149